Data Insights

Futibatinib by Otsuka Pharmaceutical for Endometrial Cancer: Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Endometrial Cancer

Data Insights

Ulotaront hydrochloride by Otsuka Pharmaceutical for Generalized Anxiety Disorder (GAD): Likelihood of Approval

Ulotaront hydrochloride is under clinical development by Otsuka Pharmaceutical and currently in Phase III for Generalized Anxiety Disorder (GAD). According...

Likelihood of Approval and Phase Transition Success Rate Model - Ulotaront Hydrochloride in Generalized Anxiety Disorder (GAD)

Data Insights

Pimitespib by Otsuka Pharmaceutical for Endometrial Cancer: Likelihood of Approval

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Pimitespib in Endometrial Cancer

Data Insights

Pimitespib by Otsuka Pharmaceutical for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - Pimitespib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Pimitespib by Otsuka Pharmaceutical for Bladder Cancer: Likelihood of Approval

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Pimitespib in Bladder Cancer

Data Insights

Pimitespib by Otsuka Pharmaceutical for Small-Cell Lung Cancer: Likelihood of Approval

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Pimitespib in Small-Cell Lung Cancer

Data Insights

Futibatinib by Otsuka Pharmaceutical for Gastric Cancer: Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Gastric Cancer

Data Insights

Futibatinib by Otsuka Pharmaceutical for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Pancreatic Ductal Adenocarcinoma

Data Insights

Futibatinib by Otsuka Pharmaceutical for Solid Tumor: Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Solid Tumor

Data Insights

Futibatinib by Otsuka Pharmaceutical for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Esophageal Squamous Cell Carcinoma (ESCC)

Data Insights

Futibatinib by Otsuka Pharmaceutical for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....

Likelihood of Approval and Phase Transition Success Rate Model - Futibatinib in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

OPB-111077 by Otsuka Pharmaceutical for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

OPB-111077 is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - OPB-111077 in Diffuse Large B-Cell Lymphoma

Data Insights

Brexpiprazole by Otsuka Pharmaceutical for Post-Traumatic Stress Disorder (PTSD): Likelihood of Approval

Brexpiprazole is under clinical development by Otsuka Pharmaceutical and currently in Pre-Registration for Post-Traumatic Stress Disorder (PTSD). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Brexpiprazole in Post-Traumatic Stress Disorder (PTSD)

Data Insights

OPC-415 by Otsuka Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval

OPC-415 is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - OPC-415 in Relapsed Multiple Myeloma

Data Insights

OPB-111077 by Otsuka Pharmaceutical for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

OPB-111077 is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - OPB-111077 in Relapsed Acute Myeloid Leukemia

Data Insights

OPB-111077 by Otsuka Pharmaceutical for Refractory Acute Myeloid Leukemia: Likelihood of Approval

OPB-111077 is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - OPB-111077 in Refractory Acute Myeloid Leukemia

Data Insights

OPB-111077 by Otsuka Pharmaceutical for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

OPB-111077 is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - OPB-111077 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

NO-13065 by Otsuka Pharmaceutical for Obesity: Likelihood of Approval

NO-13065 is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Obesity. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - NO-13065 in Obesity

Data Insights

(Cedazuridine + decitabine) by Otsuka Pharmaceutical for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

(Cedazuridine + decitabine) is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Relapsed Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - (Cedazuridine + Decitabine) in Relapsed Acute Myeloid Leukemia

Data Insights

(Cedazuridine + decitabine) by Otsuka Pharmaceutical for Refractory Acute Myeloid Leukemia: Likelihood of Approval

(Cedazuridine + decitabine) is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Refractory Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - (Cedazuridine + Decitabine) in Refractory Acute Myeloid Leukemia